肝细胞癌系统治疗药物对门静脉高压的影响  

Effect of systemic therapeutic drugs for hepatocellular carcinoma on portal hypertension

作　　者：康文迪 骆银根 杨正强 李肖 KANG Wendi;LUO Yingen;YANG Zhengqiang;LI Xiao(National Cancer Center/National Clinical Research Center for Cancer/Department of Interventional Therapy,Cancer Hospital of Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China)

机构地区：[1]国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院介入治疗科,北京100021

出　　处：《临床肝胆病杂志》2023年第7期1523-1528,共6页Journal of Clinical Hepatology

基　　金：科技部国家重点研发计划(2020YFC0122303)。

摘　　要：我国肝细胞癌(HCC)患者绝大多数来源于乙型肝炎肝硬化,而90%的肝硬化患者都会发生门静脉高压,HCC患者中合并门静脉高压占15%~30%。门静脉高压症是一组以门静脉压力升高、门体侧支循环形成为特征的临床综合征,是肝硬化最主要的并发症之一。HCC与门静脉高压两者之间相互影响,门静脉高压严重影响HCC患者预后。HCC系统治疗方案的发展,为中晚期HCC患者提供了更多的治疗选择,主要包括分子靶向药物治疗、免疫治疗和化疗等。各种HCC系统治疗药物对门静脉高压的影响也不尽相同,本文就HCC常用系统治疗药物对于门静脉高压的影响予以综述。The vast majority of patients with hepatocellular carcinoma(HCC)in China originate from hepatitis B cirrhosis,while 90%of cirrhotic patients may develop portal hypertension,and the HCC patients with portal hypertension account for 15%-30%.Portal hypertension is a group of clinical syndromes characterized by elevated portal venous pressure and formation of portal-systemic collateral circulation,and it is one of the most important complications of liver cirrhosis.HCC and portal hypertension affect each other,and portal hypertension seriously affects the prognosis of HCC patients.The development of systemic treatment regimens for HCC provides more treatment options for patients with advanced HCC,including molecular-targeted drug therapy,immunotherapy,and chemotherapy.Different systemic therapeutic drugs for HCC have different impacts on portal hypertension,and this article reviews the effect of commonly used systemic therapeutic drugs for HCC on portal hypertension.

关 键 词：癌 肝细胞 门静脉高压 治疗学 

分 类 号：R735.7[医药卫生—肿瘤]